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Ixekizumab is a humanized mono-
clonal antibody directed against
IL-17A, and it is currently under inves-
tigation in phase III trials for the treat-
ment of psoriasis and psoriatic arthritis.
As with any therapeutic antibody, ixe-
kizumab can be immunogenic (Mire-
Sluis et al., 2004; Sauerborn et al.,
2010) and induce anti-drug antibodies
(ADAs). Individual immunogenic re-
sponses to therapeutic proteins vary
greatly, ranging from having no effect
on clinical efficacy or drug levels to
neutralizing the therapeutic protein so
as to render it ineffective (Bu¨ttel et al.,
2011; Casadevall et al., 2002; Mire-
Sluis et al., 2004; Sauerborn et al.,
2010). To identify whether antibodies to
a therapeutic protein have been gener-
ated, screening immunogenicity assays
are developed to detect the presence of
ADAs in patient serum samples. How-
ever, not all assay formats are equiva-
lent (Bourdage et al., 2007; Butterfield
et al., 2010; Bu¨ttel et al., 2011; Liang
et al., 2007; Lofgren et al., 2007;
Moxness et al., 2005; Patton et al.,
2005; Sickert et al., 2008; Smith et al.,
2007; Wadhwa et al., 2003).
Two immunogenicity assays were
developed for ixekizumab, an affinity
capture elution (ACE) immunogeni-
city assay with some modifications
(Bourdage et al., 2007; Butterfield
et al., 2010) and a Meso Scale Dis-
covery (MSD) (Meso Scale Diagnostics
LLC, Rockville, MD) bridging assay
based on a previously described format
(Moxness et al., 2005), including an
upfront acid dissociation. Assays were
designed to produce approximately 5%
putative positive results in nonexposed
subjects, consistent with regulatoryAbbreviations: ACE, affinity capture elution; ADA, an
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Positive control material was ob-
tained by hyperimmunizing monkeys
with ixekizumab. Anti-ixekizumab
polyclonal antibody was affinity-
purified by passing the hyperimmune
serum over a column to which ixekizu-
mab had been covalently coupled. After
washing, bound anti-ixekizumab anti-
bodies were eluted with acid, placed
into neutral buffer, and quantitated via
protein assay. Based on results from
competition binding experiments with
IL-17A, themonkey polyclonal antibody
was observed to bind mainly the vari-
able regions of ixekizumab. In addition,
human anti-ixekizumab affinity-purified
polyclonal antibody was similarly pre-
pared from pooled serum obtained
from patients found to be ADA positive
during phase II studies. All procedures in
this protocol had institutional approval
and were in compliance with the U.S.
Department of Agriculture’s Animal
Welfare Act (9 code of federal regula-
tions Parts 1, 2, and 3) and the National
Institutes of Health, Office of Laboratory
Animal Welfare.
Sensitivity was tested by analyzing
2e2,000 ng/ml of affinity-purified
anti-ixekizumab antibody spiked into
normal human serum. Drug tolerance
was assessed by varying the concen-
tration of ixekizumab from 0.1 to 500
mg/ml in the presence of 500 ng/ml of
affinity-purified anti-ixekizumab anti-
body spiked into normal human serum.
This level of affinity-purified antibody
was chosen based on the minimal level
of acceptable sensitivity for clinical
immunogenicity screening assays
(United States Food and Drug
Administration, 2009). MSD softwareti-drug antibody; MSD, Meso Scale Discovery
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Software, Inc. San Jose, CA), were used
for fitting MSD bridging assay and
ACE assay ELISA calibration curves,
respectively. Raw data were plotted
using Microsoft Excel 2010 (Microsoft,
Redmond, WA).
The ACE assay and MSD bridging
assay formats were similar in terms of
sensitivity. Both formats showed sensi-
tivity better than 10 ng/ml (Figure 1), far
exceeding the recommended sensitivity
level of 250e500 ng/ml (United States
Food and Drug Administration, 2009).
For the ACE assay, sensitivity was almost
identical whether human or monkey
affinity-purified anti-ixekizumab anti-
body was evaluated, whereas the MSD
bridging assay showed slightly less
sensitivity with human antibody
compared with monkey antibody.
With monkey antibody, the MSD
bridging assay showed a modest drug
tolerance of approximately 10 mg/ml,
which decreased somewhat when
human antibody was tested (Figure 2).
In contrast, with monkey antibody, the
ACE assay showed a drug tolerance of
better than 200 mg/ml (far above any
expected trough exposure levels), thus
achieving roughly 20-fold greater drug
tolerance than the MSD bridging assay.
For both assays, the drug tolerance was
somewhat lower when human antibody
was evaluated (Figure 2). This may be
due to the polyclonal human antibody
having lower affinity for ixekizumab
than the monkey polyclonal antibody
obtained from hyperimmune serum.
In summary, two different immuno-
genicity screening assays for the
detection of anti-ixekizumab anti-
bodies, an ACE assay and a MSD
bridging assay, were developed and
directly compared with one another.
Although many different characteristics
of immunogenicity assays should be
evaluated, sensitivity and drug toler-
ance are two of the most critical fea-
tures and were the focus of this study.www.jidonline.org 1513
Figure 1. Sensitivity of ACE assay compared with MSD bridging assay. Affinity-purified anti-ixekizumab
antibody from monkeys or humans was spiked into normal human serum at concentrations ranging from
2-2000 ng/m. Samples were analyzed on the ACE and MSD bridging assays, with results shown as the
mean  SEM (n ¼ 2). The MSD bridging assay reports in ECL units (ECLU), while the ACE assay generates
an OD450 readout. Ab, antibody; ACE, affinity capture elution; ECLU, electrochemiluminescent units;
MSD, Meso Scale Discovery; MSDB, Meso Scale Discovery bridging; OD450, optical density at 450
nanometers.
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1514For ixekizumab, this is particularly
important, because its high-affinity
binding to its target may affect both
the sensitivity and the drug tolerance of
an assay designed to measure ADA
directed against it.
Sensitivity results obtained for the
ixekizumab ACE assay were similar to
those of the ixekizumab MSD bridging
assay, with both assays showing a
sensitivity of better than 10 ng/ml. The
drug tolerances of these two formats,
however, were markedly different.
Specifically, the drug tolerance of theFigure 2. Drug tolerance of ACE assay compared wi
anti-ixekizumab antibody from monkeys or humans w
concentration of 500 ng/ml. Samples were also spike
0.1e500.0 mg/ml and analyzed on the ACE and MSD
standard error of the mean (n ¼ 2). The MSD bridging
generates an OD450 readout. Ab, antibody; ACE, affini
units; MSD, Meso Scale Discovery; MSDB, Meso Scale
nanometers.
Journal of Investigative Dermatology (2016), VolumACE assay was roughly 20-fold greater
than the drug tolerance of the MSD
bridging format when evaluations were
performed with monkey antibody and
approximately 10-fold greater when
human antibody was tested.
To maximize the detection of clini-
cally relevant levels of ADA during
dosing, the immunogenicity assay for
ixekizumab must be able to detect ADA
in the presence of expected trough
therapeutic drug levels of ixekizumab,
which can be up to or exceed 10 mg/ml.
Failing to ensure adequate drugth MSD bridging assay. Affinity-purified
as spiked into normal human serum at a
d with concentrations of ixekizumab ranging from
bridging assays. Results are shown as the mean 
assay is reported in ECLUs, whereas the ACE assay
ty capture elution; ECLU, electrochemiluminescent
Discovery bridging; OD450, optical density at 450
e 136tolerance could lead to false-negative
results (Wang et al., 2012). The MSD
bridging assay for ixekizumab was no
longer able to detect 500 ng/ml of ADA
in the presence of greater than 10 mg/ml
of ixekizumab. In contrast, the drug
tolerance of the ACE format was suffi-
cient to detect anti-ixekizumab anti-
bodies at or even far above the
anticipated circulating concentrations
of ixekizumab. The importance of drug
tolerance for clinical immunogenicity
assays was recently illustrated by the
Center for Drug Evaluation Research at
the Food and Drug Administration,
which highlighted the lack of drug
tolerance of clinical immunogenicity
assays supporting large-molecule reg-
istrations (Wang et al., 2012).
In light of the excellent sensitivity
and superior drug tolerance of the ACE
format, this method was selected to
support ongoing phase III ixekizumab
clinical trials. Importantly, by being
able to detect clinically meaningful
levels of ADA in the presence of
expected concentrations of drug, this
assay will improve our ability to char-
acterize any clinical immunogenicity
that may be associated with
ixekizumab.
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Psoriasis is associated with autoim-
mune diseases, for example, diabetes
and inflammatory bowel disease. A link
between psoriasis and autoimmune
diseases may be the dysregulation of
tissue resident memory T cells (TRMs),
which reside long term in peripheral
tissues including the skin. This subset of
T cells probably evolved to populate
epithelial barriers throughout the body
with protective T cells reacting to
pathogens most relevant in their
respective tissues (Clark, 2015; Mackay
et al., 2013; Wakim et al., 2012). Evi-
dence of the role of TRMs in the patho-
genesis of psoriasis first came when
researchers showed that blocking
E-selectin and the transfer of T cells
from the circulation into the skin had
no effect on the skin lesions (Bhushanet al., 2002). Additional experiments
showed that nonlesional skin from pa-
tients with psoriasis developed psoriasis
upon transfer to immune-deficient mice
because of activation and proliferation
of autoreactive and pathogenic TRMs
residing in the normal-appearing skin
(Boyman et al., 2007). Because patho-
logic TRMs have been directly demon-
strated in psoriasis and because the
clinical characteristics of other human
autoinflammatory diseases suggest a
role for TRMs, we hypothesized that the
risk of autoimmune hepatitis may be
increased in patients with psoriasis.
Thus, we aimed to investigate the
association between psoriasis and
autoimmune hepatitis in a nationwide
population-based setting with adjust-
ments for confounding factors (Clark,
2015).The study comprised all Danes aged
18 years or older from 1997 to 2011.
Data on morbidity were available from
the Danish National Patient Register,
in which hospital admissions and
diagnoses have been recorded since
1978 using International Classification
of Diseases (ICD) codes (ICD-8 until
1994 and ICD-10 thereafter); hospital
procedures (including hospital-based
pharmacologic treatment, for example,
with biologic therapy) are coded as
treatment procedure (Sundhedsvæse-
nets Klassifikations System) codes. Data
including date of dispensing, formula-
tion, and quantity for all pharmacy-
dispensed medications have been
accurately registered according to the
international Anatomical Therapeutic
Chemical classification in the Danish
Registry of Medicinal Products Statistics
since 1994. Information on tax-
reported household income is regis-
tered by Statistics Denmark. We
calculated an age-standardized index
of socioeconomic status between 0 and
4 based on the average gross annualwww.jidonline.org 1515
